Intuitive Surgical (ISRG)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$366.70-0.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Intuitive Surgical grows da Vinci procedures about 16% yearly. Profit margins stay near 68%. The company actively buys back shares, returning value. It leads in robotic surgery with strong demand.
Growth may slow due to below-consensus forecasts. Margin pressure could rise from reuse concerns. The stock is expensive with a high price-to-earnings ratio.
The price is about 8% above our fair value near $396. Analysts expect 16% revenue growth, which the market largely reflects. Our fair value is 30% below the Street median, showing some valuation caution.
Breaks if: procedure growth falls below 10% YoY next year
Focus on expanding the number of da Vinci procedures performed globally.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth in da Vinci procedures. The current thesis state is intact, driven by consistent revenue growth and management's commitment to key priorities.
The market currently prices ISRG at a premium compared to peers, reflecting a justified valuation despite some concerns about execution quality. There is a slight expectations gap, indicating that the market may not fully account for potential risks.
Fundamentals are likely to remain stable, with management effectively controlling expenses and maintaining margins. However, there is a low probability of missing earnings estimates, although recent trends show a downward shift in earnings surprises.
The thesis hinges on management's ability to continue increasing da Vinci procedure volume and maintaining margins. Additionally, external factors such as sector performance and economic conditions will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Signal changed from 'favorable' to 'mild_favorable'.
Mixed, the news cuts both ways. The company reported an increase in da Vinci procedure volume, which supports growth. However, Johnson & Johnson's recent FDA approval poses a competitive threat to ISRG's market position.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: gross margin falls below 66% next year
Breaks if: share repurchases drop below $500M per quarter next year
Over the next 1 to 3 years, ISRG's performance will depend on execution and sector dynamics. Not investment advice.